EUROAPI Enters a New Chapter with Leadership Changes

EUROAPI has announced the appointment of Emmanuel Blin as Independent Chair of the Board and David Seignolle as Chief Executive Officer, following the resignations of Viviane Monges and Ludwig de Mot. This leadership transition marks a new chapter for the company, which has solidified the foundations of its FOCUS-27 strategic plan.

Emmanuel Blin, former Chief Strategy Officer at Bristol Myers Squibb, steps into his role with extensive experience, signaling EUROAPI's commitment to enhancing its standing in the Active Pharmaceutical Ingredient sector. David Seignolle, who joined EUROAPI in October 2023, brings expertise from his previous roles at TEVA Pharmaceuticals and McKinsey.

Despite the leadership changes, EUROAPI maintains its financial guidance for 2024. The company expects a year-on-year net sales decrease of 8% to 11% and a Core EBITDA margin of 4% to 7%. Full-year results are anticipated on March 3, 2025.